ClinicalTrials.gg
RecruitingNCT06923345Updated Apr 18, 2025

Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

A Phase 2 interventional study of Reduced CTV and Conventional CTV in Rectal Cancer, Neoadjuvant Therapies and Immune Checkpoint Therapy, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University — 27 open to participants now, 27 under way, 3 of them phase 3. Rectal Neoplasms · Sixth Affiliated Hospital, Sun Yat-sen University.

Planned enrollment
15th of 26
80 · median 100
Started
2025
with 7 others
Phase 2
13 of 41
10 open now
Primary completion
2027-12
later than 17 of 26 live
Registered
31st of 41
by date

Among the 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University, this one is the 15th largest by planned enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 17 of the 26 other live ones, and was the 31st registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

27 of the 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether a total neoadjuvant therapy (TNT) regimen combining long-course chemoradiotherapy, sequential chemotherapy, and PD-1 inhibitor can improve response rates, enhance tolerability, and improve prognosis in patients with locally advanced, microsatellite-stable (MSS) rectal cancer.

The main questions it aims to answer are:

Does this TNT approach improve complete response (CR) rates?

How does selective reduction of clinical target volume (CTV) to S2/S3 level compare with conventional CTV irradiation in terms of efficacy and safety?

Researchers will compare a selective CTV reduction group and a conventional CTV irradiation group to assess differences in treatment outcomes, including complete response, tumor regression grading (TRG), organ preservation, R0 resection rates, and long-term survival.

Participants will:

Receive long-course chemoradiotherapy with either conventional or reduced CTV irradiation.

Undergo sequential chemotherapy.

Receive PD-1 inhibitor treatment.

Be monitored for safety, tumor regression, and long-term survival outcomes.

03

Conditions studied

  • Rectal Cancer
  • Neoadjuvant Therapies
  • Immune Checkpoint Therapy
  • Radiotherapy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signs a written form.
  • Aged between 18 and 75 years at enrollment.
  • (ECOG) performance status of 0 or 1.
  • Expected survival of more than 2 years.
  • confirmed rectal adenocarcinoma.
  • Tumor immunohistochemistry indicating pMMR (MSH1, MSH2, MSH6, and PMS2 all positive) or genetic testing confirming MSS.
  • According to the 8th edition of the AJCC TNM classification, high-resolution MRI ± endorectal ultrasound confirms clinical staging as cT3-4NanyM0 or cTxN+M0 (stage II-III rectal cancer). MRI confirms the tumor is located below the peritoneal reflection without lateral lymph node .
  • Before study enrollment, a responsible surgical attending physician must evaluate the patient's medical history to confirm eligibility for R0 resection with curative intent.
  • No prior systemic or local anti-tumor treatment for rectal cancer, including radiotherapy, chemotherapy, immunotherapy, biologics, or small-molecule targeted therapy.
  • Willing to provide tumor tissue and peripheral blood samples for research purposes during screening and throughout the study.
  • Adequate organ function:
  • Hematology (without recent blood transfusions or growth factor support within 7 days before treatment):

    • (ANC) ≥ 1.5 × 10⁹/L (1,500/mm³)
    • count ≥ 100 × 10⁹/L (100,000/mm³)
    • ≥ 90 g/L
  • Renal function:

    • Estimated (CrCl) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula)
    • Urine protein \< 2+ or 24-hour urine protein quantification \< 1.0 g
  • Liver function:

    • Total (TBil) ≤ 1.5 × (ULN)
    • and ALT ≤ 2.5 × ULN
    • Serum albumin (ALB) ≥ 28 g/L
  • Coagulation function:

    o and APTT ≤ 1.5 × ULN

  • Cardiac function:

    o (LVEF) ≥ 50%

  • Female participants of must have a negative urine or serum pregnancy test within 3 days before starting study treatment. If a urine pregnancy test result is unclear, a confirmatory serum pregnancy test must be conducted. Participants with childbearing potential who engage in sexual activity with non-sterilized male partners must use highly effective from screening until 120 days after the last dose of study treatment. The use of periodic abstinence and fertility awareness methods is not considered acceptable contraception.
  • Definition of females of childbearing potential (FCBP): Women who have not undergone surgical sterilization (bilateral tubal ligation, bilateral oophorectomy, or total hysterectomy) or who have not been naturally for at least 12 consecutive months (confirmed by FSH levels within the postmenopausal range).
  • Highly effective contraception methods: Must have a failure rate of \<1% per year when used consistently and correctly. In addition to barrier methods, FCBP must use an additional hormonal contraceptive method (e.g., oral contraceptives).
  • Participants must be willing and able to comply with study visit schedules, treatment plans, laboratory tests, and other study-related requirements.

Exclusion criteria

Exclusion Criteria:

  • Presence of suspected lesions or locally advanced unresectable disease, regardless of disease stage.
  • Diagnosis of other within the past five years, except for patients with malignancies cured through local treatment (e.g., basal or squamous cell skin cancer, superficial bladder cancer, ductal carcinoma in situ of the breast).
  • Concurrent enrollment in another clinical study, unless it is an observational, non-interventional study or a follow-up phase of an interventional study.
  • Presence of intestinal obstruction, perforation, or bleeding requiring emergency surgery.
  • Multiple primary rectal cancers.
  • History of pelvic or abdominal radiotherapy.
  • Inability to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption.
  • Prior systemic or local anti-tumor treatment for locally advanced rectal cancer, including radical surgery, chemotherapy, radiotherapy, immunotherapy (e.g., , immune cell therapy), biological agents, or targeted therapy.
  • Use of nonspecific immunomodulatory treatment (e.g., interleukins, interferons, thymosin, TNF) within two weeks before study treatment (excluding IL-11 for thrombocytopenia); use of traditional Chinese medicine with anti-tumor indications within one week before study treatment.
  • Active disease requiring systemic treatment in the past two years, except for replacement therapy (e.g., thyroid hormone, insulin, for adrenal/pituitary insufficiency).
  • History of non-infectious pneumonitis requiring systemic glucocorticoid therapy or interstitial lung disease.
  • History of severe bleeding tendency, coagulopathy, or long-term anticoagulation therapy (e.g., atrial fibrillation with CHADS2 score ≥2).
  • Uncontrolled comorbidities, including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease, or psychiatric/social conditions limiting compliance.
  • History of myocarditis, cardiomyopathy, malignant arrhythmias; hospitalization for unstable angina, congestive heart failure, or vascular diseases (e.g., aortic aneurysm requiring surgery) within 12 months before study treatment.
  • History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea).
  • Severe infection within four weeks before study treatment, including sepsis or severe pneumonia requiring hospitalization; active infection requiring systemic therapy within ten days before study treatment (excluding antiviral therapy for or ).
  • Major surgery or severe trauma within 30 days before study treatment; minor surgery (excluding peripheral venous catheterization) within three days before study treatment.
  • Immunodeficiency history, positive test, or long-term use of systemic corticosteroids or .
  • Active tuberculosis or suspected TB requiring clinical exclusion; known active syphilis infection.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • Untreated active HBV infection (HBsAg-positive with HBV-DNA > 1000 copies/ml or 200 IU/ml); active HCV infection (HCV antibody-positive with detectable HCV-RNA).
  • administration within 30 days before study treatment or planned during the study period.
  • Known to any study drug component or history of severe hypersensitivity reactions to monoclonal antibodies.
  • History of psychiatric disorders, substance abuse, alcohol dependence, or drug addiction.
  • Pregnant or breastfeeding women.
  • Any disease, treatment, or laboratory abnormality that may confound study results, interfere with full study participation, or is not in the participant's best interest.
  • Non-malignant or tumor-related systemic diseases or symptoms causing high medical risk or uncertainty in survival assessment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Reduced CTV

    Patients will receive long-course radiotherapy with selective reduced CTV irradiation, concurrently with 3 cycles of CAPOX chemotherapy and PD-1 inhibitor. After radiotherapy, they will receive an additional 3 cycles of CAPOX chemotherapy and PD-1 inhibitor, followed by either total mesorectal excision (TME) surgery or watch-and-wait observation.

    Combination Product: Reduced CTV

  • Experimental
    Conventional CTV

    Patients will receive long-course radiotherapy with conventional CTV irradiation, concurrently with 3 cycles of CAPOX chemotherapy and PD-1 inhibitor. After radiotherapy, they will receive an additional 3 cycles of CAPOX chemotherapy and PD-1 inhibitor, followed by either total mesorectal excision (TME) surgery or watch-and-wait observation.

    Combination Product: Conventional CTV

Interventions

  • Combination productReduced CTV

    Long-course radiotherapy with selective CTV reduction (lower to S2/S3 level) + CAPOX + PD-1 inhibitor. After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response.

  • Combination productConventional CTV

    Long-course radiotherapy with conventional CTV irradiation + CAPOX + PD-1 inhibitor. After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response.

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rate

    Evaluate whether total neoadjuvant therapy (TNT) with long-course chemoradiotherapy (selective vs. conventional CTV), sequential CAPOX chemotherapy, and PD-1 inhibitor improves the complete response (CR) rate in locally advanced MSS rectal cancer.

    Time frame: From enrollment to 2 weeks after finishing TNT

Secondary outcomes

  1. Tumor regression grade (TRG)

    Time frame: From enrollment to 2 weeks after finishing TNT

  2. Tumor downstaging rate

    Time frame: From enrollment to 2 weeks after finishing TNT

  3. Watch-and-wait rate

    Time frame: From enrollment to 2 weeks after finishing TNT

  4. Sphincter preservation rate

    Time frame: From date of randomization until the date of surgery or the date of watch-and-wait for CR patients

  5. R0 resection rate

    Time frame: From date of randomization until the date of surgery or the date of watch-and-wait for CR patients

  6. 3-year event-free survival (EFS) rate

    Time frame: From enrollment to 3 years after finishing Surgery

  7. 3-year distant metastasis rate

    Time frame: From enrollment to 3 years after finishing Surgery

  8. 3-year local recurrence rate

    Time frame: From enrollment to 3 years after finishing Surgery

  9. 3-year overall survival (OS) rate

    Time frame: From enrollment to 3 years after finishing Surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 33 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 11, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06923345
Responsible party
Yanxin Luo,MD (Assistant President of the Sixth Affiliated Hospital of Sun Yat-sen University; Chief Physician of Department of Colorectal Surgery, Sixth Affiliated Hospital, Sun Yat-sen University) — Principal investigator
First posted
Apr 11, 2025
Start date
Mar 31, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 18, 2025

Study contacts

Yanxin Luo, M.D., Ph.D.
Contact
luoyx25@mail.sysu.edu.cn
+86-13826190263

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion